From the Guidelines
Hypercalcemia is primarily caused by excess bone resorption from myeloma bone disease, leading to the excessive release of calcium into the blood. This condition can result in symptoms such as polyuria and gastrointestinal disturbances, with progressive dehydration and decreases in glomerular filtration rate 1. The treatment of hypercalcemia typically involves hydration and furosemide, bisphosphonates, steroids, and/or calcitonin, with zoledronic acid being the preferred bisphosphonate for this treatment 1.
Some key points to consider in the management of hypercalcemia include:
- The use of bisphosphonates, such as zoledronic acid, to reduce bone resorption and lower calcium levels 1
- The administration of hydration and furosemide to enhance calcium excretion 1
- The potential use of steroids and/or calcitonin to further reduce calcium levels 1
- The importance of monitoring and managing symptoms, such as polyuria and gastrointestinal disturbances, to prevent progressive dehydration and decreases in glomerular filtration rate 1
It is essential to note that the treatment of hypercalcemia should be tailored to the individual patient's needs and underlying condition, with a focus on reducing morbidity, mortality, and improving quality of life. In the context of multiple myeloma, hypercalcemia is a common complication that requires prompt and effective management to prevent long-term consequences 1.
From the Research
Causes of Hypercalcemia
There are no research papers to assist in answering this question. The provided studies do not discuss the causes of hypercalcemia.
Related Conditions
- The studies discuss various topics related to diabetes, hypertension, and cardiovascular disease, but do not provide information on hypercalcemia 2, 3, 4, 5, 6.
- Hypercalcemia is a condition characterized by elevated calcium levels in the blood, but its causes are not addressed in the provided evidence.